Bolt Biotherapeutics, Inc. (BOLT) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, specifically utilizing its Boltbody immune-stimulating antibody conjugate (ISAC) platform. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of May 5, 2026, there were 1,921,567 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $26,000 | $1,222,000 |
| Net Loss | $(7,244,000) | $(11,040,000) |
| Net Loss Per Share (Basic & Diluted) | $(4.31) | $(5.76) |
| Operating Expenses | $7,627,000 | $13,337,000 |
| Cash, Cash Equivalents & Restricted Cash | $13,347,000 | $10,156,000 |
| Marketable Securities | $12,302,000 | $20,139,000 |
| Total Liquidity (Cash + Investments) | $23,900,000 | $30,295,000 |
| Accumulated Deficit | $(468,023,000) | $(438,443,000) |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue dropped 98% to $26,000 from $1.2 million in Q1 2025. Management attributes this to limited activities with collaboration partners (Toray and Genmab) pending the evaluation of BDC-4182 clinical trial results.
- Expense Reduction: Total operating expenses decreased by $5.7 million (43%) to $7.6 million. This reduction is primarily due to a 50% workforce reduction (approx. 20 employees) executed in October 2025, resulting in lower personnel, lab supply, and facility costs.
- Net Loss Improvement: Net loss narrowed by $3.8 million to $7.2 million, driven by the significant decrease in operating expenses.
- Investment Portfolio: Marketable securities decreased by approximately $7.8 million as the company utilized maturities to fund operations, with net cash provided by investing activities totaling $7.9 million.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year of the filing date. Current liquidity of $23.9 million is projected to fund operations only into early 2027.
- Capital Needs: The company must raise additional capital through equity, debt, or partnerships to continue clinical programs and operations. There is no assurance that such funding will be available on acceptable terms.
- Restructuring: A $1.5 million restructuring charge was recorded in Q4 2025. As of March 31, 2026, $266,000 remained in accrued restructuring liabilities.
- Clinical Pipeline: The Phase 1/2 trial for BDC-4182 (targeting claudin 18.2) is ongoing. Revenue recognition from collaborations is paused or minimal until the impact of these trial results is evaluated.
- Lease Obligations: The company has significant operating lease liabilities totaling $22.3 million (undiscounted future payments), with a weighted-average remaining lease term of 5.2 years.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for cash depletion and the status of any ongoing fundraising efforts or partnership negotiations.
- Collaboration Status: Confirm the timeline for the BDC-4182 clinical trial results and the specific triggers required to resume revenue recognition from Toray and Genmab agreements.
- Restructuring Completion: Monitor the payout of the remaining $266,000 in accrued restructuring liabilities and ensure no additional workforce reductions are planned.
- Lease Commitments: Assess the risk associated with the $22.3 million in future lease payments relative to the current cash balance and potential sublease income ($2.0 million total).
- Reverse Stock Split Impact: Note that all share data reflects a 1-for-20 reverse stock split effected in June 2025.